We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Proteomics Profile Early Detection Ovarian Cancer

By LabMedica International staff writers
Posted on 26 Mar 2019
High-grade ovarian cancer (HGOC) is the leading cause of mortality from gynecological malignancies, due to diagnosis at a metastatic stage. More...
Current screening options fail to improve mortality due to the absence of early-stage-specific biomarkers.

Fewer than half of ovarian cancer patients survive until five years after diagnosis. According to the American Cancer Society, this is because only about one-fifth of ovarian cancer cases are detected early, when the chances of successful treatment and recovery are highest.

A team of Israeli scientists working with the Tel Aviv University (Tel Aviv-Yafo, Israel) used proteomics and compared thousands of proteins in uterine microvesicles from 12 healthy volunteers and 12 cancer patients. Then they used machine-learning algorithms to search for patterns that could distinguish between the samples.

They postulated that a liquid biopsy, such as utero-tubal lavage (UtL), may identify localized lesions better than systemic approaches of serum/plasma analysis. Liquid biopsies from 49 HGOC patients and 127 controls were divided into a discovery and validation sets. The team tested the set's accuracy in a cohort of 152 women, 37 of who were known to have ovarian cancer. Data-dependent analysis of the samples on the Q-Exactive mass spectrometer provided depth of 8,578 UtL proteins in total, and on average ~3,000 proteins per sample.

The test had 70% diagnostic sensitivity, meaning that it correctly detected cancer 25 of the 37 study participants who truly had cancer; and 76% specificity, meaning that it correctly identified about three out of every four healthy volunteers as healthy. It outperformed previous proteomics-based tests, which had less than 60% sensitivity. They used support vector machine algorithms for sample classification, and crossed three feature-selection algorithms, to construct and validate a 9-protein classifier to achieve the sensitivity and the specificity. The signature correctly identified all Stage I lesions. These results demonstrate the potential power of microvesicle-based proteomic biomarkers for early cancer diagnosis.

The authors propose that their test may be useful for young women whose risk of developing ovarian cancer is known to be high. They also believe that the method of isolating microvesicles from bodily fluids to detect fainter cancer signals shows promise for other difficult-to-detect types of cancer. Keren Levanon, MD, PhD, an Oncologist and a senior author of the study, said, “We developed a diagnostic set of nine proteins that distinguishes women with ovarian cancer from healthy women with greater sensitivity and specificity than reported before.” The study was published on February 13, 2019, in the journal Molecular & Cellular Proteomics.

Related Links:
Tel Aviv University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.